申请人:——
公开号:US20030176668A1
公开(公告)日:2003-09-18
A C-nitroso compound having a molecular weight ranging from about 225 to about 1,000 (from about 225 to about 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to about 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. The compound is preferably water-soluble and preferably contains a carbon alpha to the nitrosylated carbon which is part of a ketone group. In one embodiment, the C-nitroso compound is obtained by nitrosylation of a conventional drug or such drug modified to modify the carbon acid pKa thereof When such drug is a nonsteroidal anti-inflammatory drug, the resulting C-nitroso compound functions as a COX-1 and COX-2 inhibitor without the deleterious effects associated with COX-1 inhibition but with the advantageous effects associated with COX-1 and COX-2 inhibition. One such C-nitroso compound is a nitrosoketoibuprofen. A specific example of this kind of compound is isolated as dimeric 2-[4′-(&agr;-nitroso)isobutyrylphenyl]propionic acid. In another case, the C-nitroso compound contains the moiety
1
where X is S, O or NR. One embodiment is directed to COX-2 inhibitors where a tertiary carbon atom and/or an oxygen atom and/or a sulfur atom is nitrosylated.
一种分子量范围从约225到约1,000(口服时约225到约600)的C-亚硝基化合物,基于单体,其中亚硝基固定在三级碳上,该化合物通过亚硝基化具有pKa小于约25的碳酸的作用,并且有利于作为NO供体。当该化合物从pKa小于约10的碳酸中获得时,使用微摩尔浓度时可提供血管舒张作用,并且该活性在谷胱甘肽的作用下可在纳摩尔浓度下获得。当该化合物从pKa范围约为15到20的碳酸中获得时,可在纳摩尔浓度下获得血管舒张作用,无需谷胱甘肽。该化合物最好是水溶性的,并且最好包含与亚硝基化碳的α-碳相关的酮基团。在一种实施例中,该C-亚硝基化合物是通过亚硝基化传统药物或该药物的改性物来获得的,以改变其碳酸的pKa。当该药物是非甾体抗炎药时,所得的C-亚硝基化合物起到COX-1和COX-2抑制剂的作用,而不具有与COX-1抑制相关的有害效果,但具有与COX-1和COX-2抑制相关的有利效果。其中一种C-亚硝基化合物是亚硝基酮布洛芬。这种化合物的一个具体例子是二聚体2-[4'-(α-亚硝基)异丁酰基苯基]丙酸。在另一种情况下,C-亚硝基化合物包含1中的基团,其中X为S、O或NR。一种实施例是针对COX-2抑制剂,其中三级碳原子和/或氧原子和/或硫原子被亚硝基化。